Global reach Kamada operates as a global biopharmaceutical company with six FDA-approved products sold in more than 30 countries, presenting multiple cross-border sales opportunities and partnerships in diverse regulatory environments.

Rare disease focus The portfolio targets rare and serious conditions with limited treatment alternatives, indicating high-value needs, premium pricing opportunities, and potential for expanded access programs and payer partnerships.

Strong cash position Recent financial highlights include record-high revenue and profitability for the first half of 2026 and a declared cash dividend, suggesting financial stability that could support channel expansion, joint ventures, and co-promotion arrangements.

Plasma-derived leadership As a leader in the specialty plasma-derived field, Kamada offers established expertise, scalable manufacturing capabilities, and credibility that can drive collaboration with CROs, contract manufacturers, and distributors seeking trusted plasma-based therapies.

Strategic visibility Active engagement with investors and near-term growth signals in earnings and market commentary indicate momentum; leverage executive presence at conferences and investor events to pursue strategic partnerships, licensing, and distribution deals.